ATE388722T1 - THERAPEUTISCHE FRAGMENTE DES ßVON WILLEBRANDß FAKTORS - Google Patents

THERAPEUTISCHE FRAGMENTE DES ßVON WILLEBRANDß FAKTORS

Info

Publication number
ATE388722T1
ATE388722T1 AT96918137T AT96918137T ATE388722T1 AT E388722 T1 ATE388722 T1 AT E388722T1 AT 96918137 T AT96918137 T AT 96918137T AT 96918137 T AT96918137 T AT 96918137T AT E388722 T1 ATE388722 T1 AT E388722T1
Authority
AT
Austria
Prior art keywords
fragment
solution
vwf
denaturant
aqueous solution
Prior art date
Application number
AT96918137T
Other languages
English (en)
Inventor
David L Farb
Michael E Hrinda
Ted C K Lee
Christopher P Prior
David Weber
Original Assignee
Aventis Behring L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Behring L L C filed Critical Aventis Behring L L C
Application granted granted Critical
Publication of ATE388722T1 publication Critical patent/ATE388722T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96918137T 1995-06-07 1996-06-06 THERAPEUTISCHE FRAGMENTE DES ßVON WILLEBRANDß FAKTORS ATE388722T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/487,445 US5847086A (en) 1991-06-20 1995-06-07 Therapeutic fragments of von Willebrand factor

Publications (1)

Publication Number Publication Date
ATE388722T1 true ATE388722T1 (de) 2008-03-15

Family

ID=23935756

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918137T ATE388722T1 (de) 1995-06-07 1996-06-06 THERAPEUTISCHE FRAGMENTE DES ßVON WILLEBRANDß FAKTORS

Country Status (11)

Country Link
US (1) US5847086A (de)
EP (1) EP0833659B1 (de)
JP (1) JP4233114B2 (de)
KR (1) KR100486472B1 (de)
AT (1) ATE388722T1 (de)
AU (1) AU716449B2 (de)
CA (1) CA2223702C (de)
DE (1) DE69637464T2 (de)
ES (1) ES2302336T3 (de)
MX (1) MX9709893A (de)
WO (1) WO1997018834A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387711B1 (en) * 2000-08-11 2002-05-14 Quest Diagnostics Investments Incorporated Liquid intact parathyroid hormone (PTH) standards
US6905886B2 (en) * 2000-08-11 2005-06-14 Quest Diagnostics Investments Incorporated Preservative solutions
EP1531855A4 (de) * 2002-01-10 2009-07-22 Osteotrophin Llc Behandlung von knochenerkrankungen mit skelettalen anabolika
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070101226A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 앱타머의 약화학
EP1789096A4 (de) 2004-09-07 2009-07-08 Archemix Corp Aptamere für den von-willebrand-faktor und ihre verwendung als therapeutika für thrombotische erkrankungen
US20080160024A1 (en) * 2006-12-07 2008-07-03 Board Of Trustees Of The University Of Arkansas Inhibition of cancer metastasis
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
SG187410A1 (en) * 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
EP2349314B1 (de) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilisierte rekombinante vwf-formulierungen
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
ES2992308T3 (es) * 2018-06-29 2024-12-11 Ribomic Inc Preparación de aptámero

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
EP0255206B1 (de) * 1986-05-30 1995-03-22 The Scripps Research Institute Peptide, die die Bindung des Von-Willebrand-Faktors inhibieren
US5238919A (en) * 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5530100A (en) * 1990-05-07 1996-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for purification of recombinantly produced proteins
AU1757592A (en) * 1991-03-27 1992-11-02 Scripps Research Institute, The Therapeutic fragments of von willebrand factor
EP0590048B1 (de) * 1991-06-20 2004-12-01 Aventis Behring L.L.C. Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor
WO1993022336A1 (en) * 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
US5827773A (en) * 1997-03-07 1998-10-27 Sharp Microelectronics Technology, Inc. Method for forming polycrystalline silicon from the crystallization of microcrystalline silicon

Also Published As

Publication number Publication date
KR19990022634A (ko) 1999-03-25
ES2302336T3 (es) 2008-07-01
DE69637464D1 (de) 2008-04-24
EP0833659A4 (de) 2003-01-15
JP2001517197A (ja) 2001-10-02
AU6047196A (en) 1997-06-11
EP0833659B1 (de) 2008-03-12
MX9709893A (es) 1998-08-30
DE69637464T2 (de) 2008-11-06
WO1997018834A1 (en) 1997-05-29
CA2223702C (en) 2008-07-29
JP4233114B2 (ja) 2009-03-04
CA2223702A1 (en) 1997-05-29
AU716449B2 (en) 2000-02-24
KR100486472B1 (ko) 2005-09-02
US5847086A (en) 1998-12-08
EP0833659A1 (de) 1998-04-08

Similar Documents

Publication Publication Date Title
Stenflo et al. Vitamin K and the biosynthesis of prothrombin: I. Identification and purification of a dicoumarol-induced abnormal prothrombin from bovine plasma
ATE388722T1 (de) THERAPEUTISCHE FRAGMENTE DES ßVON WILLEBRANDß FAKTORS
KR900701823A (ko) 혈장단백질의 크로마토그래피 분리법
KR850004593A (ko) 인자 ⅷ:c의 정제방법
ATE251668T1 (de) Reinigung von plasmafraktion
AU591397B2 (en) Method of preparing alpha-1-proteinase inhibitor
ATE187462T1 (de) Reinigung von alpha-l-proteinaseinhibitor mittels neuen chromatographischen trennungsbedingungen
SE9603068D0 (sv) Process for purifying a protein
DE3751389D1 (de) Verfahren zur Trennung von Proteinen.
ITFI920078A1 (it) Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
AU2253392A (en) Therapeutic fragments of von willebrand factor
KR840003422A (ko) 균질한 인체 면역 인터페론의 제조방법
EP0656419A4 (de) Verfahren zur hochreinigung von menschlichem serumalbumin.
KR930023371A (ko) 사람의 뇨로부터의 유용 단백질의 생산방법
MY119366A (en) A process for the preparation of factor ix from biological sources
FR2632302B1 (fr) Procede de recuperation d'acide citrique a partir d'une liqueur en contenant
DE69303941D1 (de) Verfahren zur Herstellung von hochreinem Fibrinogen
ATE278705T1 (de) Verfahren zur reinigung von proteinen
EP0085220A3 (de) Verfahren zur Reinigung des Hormons der vorderen Hypophyse
KR890008167A (ko) 인자 viii의 정제에 사용하기 위한 펩타이드 및 그 제조방법
Ninfali et al. Goat immunoglobulin purification on phosphocellulose and DEAE Affi-Gel blue
SE9303822D0 (sv) Method for purification
HUT35289A (en) Immune interferon and process for its purification
KR940005284A (ko) 면역친화성 크로마토그래피에 의한 플라스미노겐 활성화제 억제제 2의 정제방법
IT9019132A1 (it) Assorbenti tiofilici

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0833659

Country of ref document: EP

EEFA Change of the company name